Posted on February 25, 2008 by jrowley
Q Therapeutics, a cell therapy company focusing on neural applications, recently announced a $15M series B financing that included funding from multiple venture capital (VC) groups as well as biotech tools provider Invitrogen. Q’s lead product, Q-Cells™, is an allogeneic product intended to restore function to damaged neurons by providing trophic (e.g. cytokines, growth [...]
Filed under: Bioprocessing, Clinical Trials, Company Profiles, MS, Manufacturing, Neural Repair, Q Therapeutics, Regenerative Medicine, adult stem cell, stem cells | Tagged: symbiotic business relationships, cell therapy tools, cell therapy development, GMP-grade kits and reagents | 2 Comments »
Posted on January 22, 2008 by jrowley
Pervasis Therapeutics announced that they have raised $9.75M to further develop their allogenic tissue engineered endothelial cell (EC) product for vascular health indications. Their Vascugel product is comprised of ECs grown in 3D collagen sponges that are implanted externally on blood vessels to prevent them from occluding. Pervasis has proven safety in a Phase I [...]
Filed under: Biomaterials, Bioprocessing, Clinical Trials, Company Profiles, Manufacturing, Pervasis, Regenerative Medicine, cell delivery, combination products, tissue engineered product, vascular regeneration | Tagged: end stage renal disease, endothelial cells, ESRD, gelfoam, tissue engineering, vascular health | No Comments »
Posted on January 9, 2008 by jrowley
The WuXi acquisition of Apptec (posted last week) is continuing the trend of consolidation in the cell manufacturing sector. It is similar to Lonza’s (a Swiss company) purchase of Cambrex’s biologics division in 2006, and GE’s purchase of Wave Biotech in mid-2007. Lonza is currently the largest manufacturer of cells for therapy, and has process [...]
Filed under: Apptec, BD, Bioprocessing, Invitrogen, JNJ, Lonza, Manufacturing, Progenitor Cell Therapy, Regenerative Medicine, Stem Cells Inc, WuXi Pharmatech | 1 Comment »
Posted on January 7, 2008 by jrowley
WuXi (pronounced Woo-See) Pharmatech, a contract research organization (CRO) based in China, announced the acquisition of MN-based Apptec Laboratory Services. WuXi acquired Apptec to gain an immediate US footprint, better access to the US market, and important biologics expertise to expand outside the world of small molecules. This biologics expertise includes Apptec’s cell [...]
Filed under: Apptec, BD, Bioprocessing, Company Profiles, Invitrogen, JNJ, Lonza, Manufacturing, Regenerative Medicine, WuXi Pharmatech, business models | 1 Comment »
Posted on December 13, 2007 by jrowley
Organogenesis, one of the pioneering tissue engineering companies, is partnering with China’s National Tissue Engineering Center (NTEC) to bring Organogenesis’ regenerative therapies to the Chinese marketplace. NTEC is a Shanghai-based private company that is funded by the Chinese government, and it was launched by a Harvard/MIT-trained plastic surgeon, Dr. Yiling Cao. The two companies [...]
Filed under: Bioprocessing, Joint Ventures, Manufacturing, Regenerative Medicine, business models | Tagged: china, China's National Tissue Engineering Center, joint venture, Organogenesis, Regenerative Medicine | 1 Comment »
